- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05275569
Personalized Electroacupuncture Treatment for Chemotherapy-induced Nausea and Vomiting in Breast Cancer (PET)
March 22, 2022 updated by: Jiuda Zhao, Affiliated Hospital of Qinghai University
Personalized Electroacupuncture Treatment Combined With Standard Antiemetic Drugs for Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer Receiving Highly Emetogenic Chemotherapy
This study aims to evaluate electroacupuncture as an antiemetic treatment compared with sham acupuncture in patients with breast cancer, receiving highly emetogenic chemotherapy (HEC).
Moreover, it will analyze the association between single nucleotide polymorphism and the antiemetic outcomes of electroacupuncture.
Study Overview
Status
Recruiting
Conditions
Detailed Description
This is a parallel-group, triple-blinded (participants, evaluators and statisticians), randomized controlled study that investigates the antiemetic role of electroacupuncture combined with standard antiemetic drugs for patients with breast cancer receiving HEC.
Neurokinin-1 receptor antagonists (NK-1RAs), serotonin receptor antagonists [5HT3RA] and dexamethasone will be administered prior to initiation of HEC on Day 1 in both groups.
Electroacupuncture or sham acupuncture will be randomly administered to the two groups.
Subjects will record all events of emesis and the use of rescue antiemetic medication for nausea and/or vomiting.
Blood samples will be collected and be analyzed to whether genetic polymorphisms can be used to predict Electroacupuncture outcomes in patients with breast cancer receiving HEC.
Primary and secondary outcomes and adverse events will be evaluated.
Study Type
Interventional
Enrollment (Anticipated)
234
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jiuda Zhao, MD
- Phone Number: 869716230893
- Email: jiudazhao@126.com
Study Locations
-
-
Qinghai
-
Xining, Qinghai, China, 810000
- Recruiting
- Jiuda Zhao
-
Contact:
- Jiuda Zhao
- Phone Number: 869716230893
- Email: jiudazhao@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- 18 years of age or older, of any nationality;
- Eastern Cooperative Oncology Group performance status of 0-2;
- For patients with breast cancer, molecular typing is not limited, receiving for the first time chemotherapy with anthracyclines+ cyclophosphamide (EC or AC) or carboplatin (AUC≥4)/cisplatin -based HEC regimen. Patients with previous chemotherapy use could be enrolled if they received it >3 months;
- Predicted life expectancy of ≥3 months;
- Adequate bone marrow, kidney, and liver function;
- Adequate contraception if premenopausal women;
- Written informed consent by the patient before enrolment.
Exclusion Criteria:
- Patients already submitted to chemotherapy;
- Is scheduled to receive any non-HEC on Day 1;
- Received or is scheduled to receive radiation therapy to the abdomen, pelvis, head and neck within 1 week prior to Day 1 or between Days 1 to 5 in cycle 1;
- Has symptomatic primary or metastatic symptomatic central nervous system malignancy causing nausea and/or vomiting;
- Have ongoing emesis or CTCAE grade 2 or greater nausea;
- Significant mental conditions;
- Any allergies to study drug, antiemetics or dexamethasone;
- Significantly abnormal laboratory values (platelets, absolute neutrophils, AST, ALT, bilirubin or creatinine);
- Patients who are pregnant or breast-feeding;
- Inflammatory skin reaction;
- Has lymphedema in acupuncture stimulation area;
- Patients who are afraid of electroacupuncture stimulation or allergic to stainless steel needles;
- Received acupuncture treatments for any conditions less than 4 weeks before HEC;
- The current use of any drugs with antiemetic activity (e.g. 5-HT3 RA, dopamine receptor antagonist, minor tranquilizer, antihistamine);
- Patients with concomitant severe diseases or with a predisposition to emesis such as gastrointestinal obstruction, active peptic ulcer, hypercalcemia and symptomatic brain metastasis;
- Patients receiving other concomitant antiemetic treatments or submitted to antiemetic treatments in the 24 hours before chemotherapy;
- Patients receiving concomitant steroids, except when administered at physiologic doses;
- Patients receiving concomitant benzodiazepines, except when used for nocturnal sedation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: True acupuncture + standard antiemetic treatment
|
Participants will receive electroacupuncture once daily from day 1 to day 4.
The acupuncturists will insert needles into the acupoints and manipulate the needles until"de qi"sensation is achieved and reported by the participants.
Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz.
They will receive fosaprepitant 150 mg intravenous IV + palonosetron 0.25 mg IV + dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy.
|
Placebo Comparator: Sham acupuncture + standard antiemetic treatment
|
The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value.
Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid "de qi" sensation.
They will receive fosaprepitant 150 mg intravenous IV + palonosetron 0.25 mg IV + dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post-chemotherapy(the antiemetic drugs are the same as the true acupuncture group).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Patients With Significant Nausea, Rescue Treatment and Number of Times of Vomiting Occurs After chemotherapy (complete protection).
Time Frame: 120 hours
|
The proportion of patients achieving complete protection is defined as patients who have no vomiting, no rescue treatment, no significant nausea that was assessed by visual analog scale (VAS, this is a Visual Analogue Scale was used to assess the incidence and intensity of nausea daily, a 100-mm horizontal bar containing no marking except for the anchor point at each end: left, no nausea; right, worst nausea.
No nausea was defined as a VAS scores < 5mm, no significant nausea was defined as a VAS scores < 25mm), and maximum less than 25 mm during the first 120 hours after the initiation of chemotherapy (The definition is different from the complete response in the "Secondary endpoints" section).
|
120 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The relationship between single nucleotide polymorphism genotypes and the proportion of patients with significant nausea, rescue treatment and number of times of vomiting occurs after chemotherapy (complete protection).
Time Frame: 120 hours
|
The single nucleotide polymorphism genotypes will be analyzed by detecting different bases (A, T, C and G) in peripheral blood DNA.
The proportion of patients with different single nucleotide polymorphism genotypes will be analyzed.
The proportion of patients achieving complete protection is defined as patients who have no vomiting, no rescue treatment, no significant nausea that was assessed by VAS as mentioned above, and maximum less than 25 mm during the first 120 hours after the initiation of chemotherapy.
We will analyze the relationship between the proportion of patients with different single nucleotide polymorphism genotypes and the proportion of patients with complete protection.
|
120 hours
|
The proportion of patients who have no vomiting/retching or rescue medications after chemotherapy during 0 to 24 hours (acute complete response)
Time Frame: 24 hours
|
The proportion of patients achieving acute complete response is defined as patients who have no vomiting/retching or rescue medications during 0 to 24 hours after the initiation of chemotherapy.
|
24 hours
|
The proportion of patients who have no vomiting/retching or rescue medications after chemotherapy during 24 to 120 hours (delayed complete response)
Time Frame: 120 hours
|
The proportion of patients achieving delayed complete response is defined as patients who have no vomiting/retching or rescue medications during delayed 24 to 120 hours after the initiation of chemotherapy.
|
120 hours
|
Number of times of no vomiting in the acute stage (0 to 24 hours) after chemotherapy (no vomiting in the acute stage)
Time Frame: 24 hours
|
The proportion of patients who have no vomiting during the acute stage (0 to 24 hours) after the initiation of chemotherapy.
|
24 hours
|
Number of times of no vomiting in the delayed stage (24 to 120 hours) after chemotherapy (no vomiting in the delayed stage)
Time Frame: 120 hours
|
The proportion of patients who have no vomiting during the delayed stage (24 to 120 hours) after the initiation of chemotherapy.
|
120 hours
|
Number of times of no vomiting in the overall stage (0 to 120 hours) after chemotherapy (no vomiting in the overall stage)
Time Frame: 120 hours
|
The proportion of patients who have no vomiting during 0 to 120 hours after the initiation of chemotherapy.
|
120 hours
|
The proportion of no nausea (no nausea in the overall stage)
Time Frame: 120 hours
|
The proportion of patients who have no nausea (VAS# 5 mm) that was assessed by VAS, and maximum less than 5 mm during the first 120 hours after the initiation of chemotherapy.
|
120 hours
|
The proportion of no significant nausea (no significant nausea in the overall stage)
Time Frame: 120 hours
|
The proportion of patients who have no significant nausea (VAS# 25 mm) that was assessed by VAS, and maximum less than 25 mm during the first 120 hours after the initiation of chemotherapy.
|
120 hours
|
The proportion of patients achieving total control (total control in the overall stage)
Time Frame: 120 hours
|
The proportion of patients achieving total control is defined as patients who have no vomiting, no rescue treatment, no nausea assessed by VAS, and maximum less than 5 mm during the first 120 hours after the initiation of chemotherapy.
|
120 hours
|
Constipation
Time Frame: 120 hours
|
The proportion of patients with constipation evaluated by Common Terminology Criteria for adverse events Version 4.0 during 0 to120 hours after the initiation of chemotherapy.
|
120 hours
|
Diarrhea
Time Frame: 120 hours
|
The proportion of patients with diarrhea evaluated by Common Terminology Criteria for adverse events Version 4.0 during 0 to120 hours after the initiation of chemotherapy.
|
120 hours
|
Fatigue
Time Frame: 120 hours
|
The proportion of patients with fatigue evaluated by Common Terminology Criteria for adverse events Version 4.0 during 0 to120 hours after the initiation of chemotherapy.
|
120 hours
|
Insomnia
Time Frame: 120 hours
|
The proportion of patients with insomnia evaluated by Common Terminology Criteria for adverse events Version 4.0 during 0 to120 hours after the initiation of chemotherapy.
|
120 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 15, 2022
Primary Completion (Anticipated)
June 30, 2024
Study Completion (Anticipated)
December 31, 2024
Study Registration Dates
First Submitted
January 25, 2022
First Submitted That Met QC Criteria
March 8, 2022
First Posted (Actual)
March 11, 2022
Study Record Updates
Last Update Posted (Actual)
April 4, 2022
Last Update Submitted That Met QC Criteria
March 22, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AHQU-2022002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on True acupuncture + standard antiemetic treatment
-
Cairo UniversityRecruitingObesity | Tinnitus, Subjective | LipidsEgypt
-
Xuanwu Hospital, BeijingUnknownAlzheimer's DiseaseChina
-
Taipei Medical UniversityCompletedSalivary Gland DiseasesTaiwan
-
Wake Forest University Health SciencesCompletedHead and Neck Cancer | Radiation Toxicity | Radiation-Induced Xerostomia | Oral Complications of Chemotherapy and Head/Neck RadiationUnited States
-
Instituto Brasileiro de Controle do CancerUnknownPeripheral Neuropathy Due to ChemotherapyBrazil
-
Loyola UniversityInterstitial Cystitis Association (ICA)CompletedInterstitial Cystitis | Painful Bladder SyndromeUnited States
-
Paul CrawfordRecruiting
-
Mike O'Callaghan Military HospitalTerminated
-
US Department of Veterans AffairsCompletedSleep Initiation and Maintenance Disorders | Stress Disorders, Post-TraumaticUnited States
-
Scripps HealthRecruitingHypotension | Congestive Heart FailureUnited States